This Company Says It's One Step Closer to Transforming Cancer Treatment with its Latest Groundbreaking Immunotherapy

Photo by Martha Dominguez de Gouveia on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

PDS Biotechnology Inc. PDSB, a clinical-stage biotech company developing a pipeline of cancer immunotherapies, has been one of the best-performing stocks on the Nasdaq Stock Market over the past year. 

With growth rates topping more than 500% — PDS Biotech has outperformed the likes of Pfizer Inc. PFE, Agios Pharmaceuticals Inc. AGIO, Surface Oncology Inc. SURF and many more industry titans. 

PDS Biotech says its success has been driven by the promising development of Versamune®-based immunotherapy products. Versamune® is the company’s proprietary T-cell activating technology designed to train the immune system to protect and fight against a number of diseases - including cancer.

T-cells are a critical component of the immune system that help protect the body from diseases and have shown the potential to defeat cancer.

PDS Biotech’s lead product PDS0101 has succeeded in generating optimistic results as an effective cancer treatment — especially for HPV-associated cancers including anal, cervical, head and neck, penile, vaginal and vulvar cancers.

When paired with a tumor-specific protein, Versamune® stimulates a robust immune response that helps T-cells recognize the tumor-specific protein as a molecular marker.  The activated T-cells specifically target and attack cancers that match the molecular marker.

PDS Biotech’s Versamune®-based cancer immunotherapies have generated highly promising results delivering a groundbreaking combination of potency and safety in fighting cancer. They show strong promise to evolve as a new class of effective cancer treatments that are both more effective and less harmful than standard treatments like chemotherapy.

This characteristic of Versamune® is incredibly significant, considering that the majority of cancer treatments today often result in debilitating side effects. Combination treatments, which are becoming more common in treating cancer, typically result in even more significant side effects.

Versamune®-based products demonstrate an impressive efficacy when used alone — but they also exhibit a powerful synergy with checkpoint inhibitor therapy. Studies have supported the duo’s ability to work together to attack and destroy cancer cells more effectively than either treatment alone.

PDS Biotech has several significant milestones over the next 9 months that it is aiming to complete.

Interim data presented by the National Cancer Institute (NCI) studying PDS0101 in combination with two other immunotherapies, demonstrated an almost 70% efficacy rate in patients with advanced HPV-related cancer who had failed multiple prior treatments. In comparison, the standard efficacy rate for this patient population with FDA-approved standard of care treatment is about 15%.

PDS Biotech expects to complete enrollment for the NCI-led trial and the subsequent release of additional results from the trial in the next few months. PDS Biotech also expects to report interim results from a second Phase 2 trial studying PDS0101 in combination with Merck & Co.’s MRK blockbuster immunotherapy Keytruda in a study being run in partnership with Merck in the first half of 2022. A third Phase 2 trial studying PDS0101 in combination with chemotherapy in locally advanced cervical cancer is being led by MD Anderson Cancer Center.  Interim results from that trial are expected in the middle of 2022. 

In addition, PDS Biotech is progressing additional pipeline products into clinical trials for the treatment of prostate, breast, colorectal, lung and ovarian cancers by mid-2022.

Learn more about PDS Biotech’s cancer treatments at https://www.pdsbiotech.com/. You can also review the company’s investor information here.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.